Skip to main content
. Author manuscript; available in PMC: 2022 Oct 20.
Published in final edited form as: Toxicol Appl Pharmacol. 2022 Aug 9;452:116193. doi: 10.1016/j.taap.2022.116193

Fig. 1.

Fig. 1.

AsIII impairs the erythro-megakaryocytic lineage commitment of early HPCs. (A) Percentages of surface marker defined common myeloid progenitors (CMP) and (B) erythro-megakaryocytic progenitors (MEP), and (C) myeloid progenitors (Pre-GM and GMP) after 48 h exposure of HPCs to 0, 100, or 500 nM AsIII. Data are expressed as mean ± SD. Statistically significant differences compared to untreated control in one-way ANOVA followed by Tukey’s post hoc test (n = 3/group, *p < 0.05, **p < 0.01, ****p < 0.0001).